HC Wainwright Reaffirms Buy Rating for Trevi Therapeutics (NASDAQ:TRVI)

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $21.00 price objective on the stock. HC Wainwright’s price target would suggest a potential upside of 43.25% from the company’s previous close.

TRVI has been the subject of a number of other reports. D. Boral Capital reiterated a “buy” rating and set a $19.00 price target on shares of Trevi Therapeutics in a report on Friday, April 17th. Needham & Company LLC cut their price target on Trevi Therapeutics from $24.00 to $23.00 and set a “buy” rating for the company in a report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Trevi Therapeutics in a report on Monday, April 20th. Morgan Stanley cut their price target on Trevi Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a report on Wednesday, March 18th. Finally, Oppenheimer reiterated an “outperform” rating on shares of Trevi Therapeutics in a report on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $21.50.

Trevi Therapeutics Stock Up 1.9%

Shares of TRVI stock opened at $14.66 on Wednesday. Trevi Therapeutics has a 12 month low of $5.38 and a 12 month high of $16.12. The firm has a market cap of $1.89 billion, a PE ratio of -45.81 and a beta of 1.07. The stock has a 50 day moving average of $12.57 and a 200-day moving average of $11.90.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). As a group, equities analysts predict that Trevi Therapeutics will post -0.46 EPS for the current fiscal year.

Institutional Trading of Trevi Therapeutics

Several large investors have recently made changes to their positions in the business. Fifth Third Bancorp bought a new stake in shares of Trevi Therapeutics during the first quarter worth $1,531,000. Candriam S.C.A. bought a new stake in shares of Trevi Therapeutics during the first quarter worth $9,229,000. Hsbc Holdings PLC bought a new stake in shares of Trevi Therapeutics during the first quarter worth $205,000. Simplify Asset Management Inc. bought a new stake in shares of Trevi Therapeutics during the first quarter worth $780,000. Finally, Peregrine Capital Management LLC grew its holdings in shares of Trevi Therapeutics by 4.5% during the first quarter. Peregrine Capital Management LLC now owns 530,451 shares of the company’s stock worth $6,328,000 after purchasing an additional 22,766 shares during the last quarter. Institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.